

**PROFIT GUIDANCE FOR THE SECOND HALF AND FULL FINANCIAL YEAR ENDED
31 DECEMBER 2022**

The Board of Directors of CDW Holding Limited (the “**Company**”, and together with its subsidiaries, the “**Group**”) would like to announce that following a preliminary review of the information currently available to the Board, including the unaudited results for the second half of the financial year ended 31 December 2022 (“**2H2022**”) and the full financial year ended 31 December 2022 (“**FY2022**”), the Company is expected to report a significant improvement in its consolidated profit (the “**Profit**”) for FY2022.

Improvement in LCD Backlight Unit Segment and LCD Parts and Accessories Segment

Since the Group’s backlight unit productions were temporarily suspended in April and May 2022 due to COVID-19 restrictions in Shanghai as previously announced, the Group’s total delivery volume of LCD backlight units for automotive digital instrument panels saw a recovery to a higher level compared to the prior year. In addition, more than 50% of the Group’s LCD Backlight Unit delivered during the year were for larger automotive digital instrument panels (over 10-inches), compared with 33% in the prior year.

With the expectation of economic recovery from the COVID-19 pandemic in the United States of America, the Group received substantial orders for mobile payment devices for its original equipment manufacturer business under the LCD Parts and Accessories Segment. Orders for advanced model payment devices has enhanced the performance of this segment.

Gain on Deemed Disposal of ABio Shares

With reference to the Company’s announcement dated 4 April 2022, the Company’s wholly owned subsidiary, Tomoike Industrial (H.K.) Limited (the “**Subsidiary**”), has completed the acquisition (the “**Purchase**”) of two hundred thousand (200,000) shares of the common stock of A Biotech Co., Ltd. (“**ABio**”) from Mr. Yoshimi Koichi at the Purchase price of KRW 9,200 per share, representing 23.08% of the total issued and paid-up capital of ABio.

Upon completion of the transaction, the Company is expecting to recognise:

1. a gain on deemed disposal on previously held 48.46% equity interest of ABio of approximately KRW 12,672,000,000 (Approx. US\$10.3 million); and
2. a goodwill which measured as the excess of the sum of the consideration transferred and the fair value of the Group’s previously held equity interest in ABio, over the net fair value of the identifiable assets acquired and the liabilities assumed and the amount of non-controlling interests in ABio as at acquisition date of approximately KRW 17,511,000,000 (Approx. US\$14.4 million).

The Board of Directors have considered that as the gain on deemed disposal was derived from the increase in fair value is a non-cash item, it will not have any impact on the operating cash flows of the Group.

As the Company is working with the independent qualified professional valuer, AVISTA Group of Hong Kong for the final stage of completing the fair value assessment of ABio shares, further details of the Group's financial performance and operating profit will be disclosed when the Company finalises its unaudited consolidated FY2022 financial results, which will be announced on or before 1 March 2023.

Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company. If in doubt as to the action they should take, shareholders and investors should consult their stockbrokers, bankers, solicitors, accountants, tax advisers or other professional advisers.

BY ORDER OF THE BOARD

YOSHIKAWA MAKOTO

Chairman and Chief Executive Officer

20 February 2023